Hangzhou Huiyidao Technology Co., Ltd. (Huiyidao) has unveiled a sweeping overhaul of its brand identity, strategic vision, and core mission. This rejuvenation is epitomized by the introduction of the new brand moniker, “AIMed,” signifying its unwavering dedication to harnessing AI technology within the realm of translational medicine. The company's renewed vision is to “lay the foundation for the triumph of global translational medicine through dependable AI,” positioning itself as an intelligent nexus and catalyst for this critical field on a worldwide scale.

Since its inception in 2019, AIMed has been at the forefront of developing AI solutions that are intricately tailored to the nuances of translational medicine. By capitalizing on a wealth of accumulated data and integrating its proprietary pharmaceutical vertical large model with a comprehensive knowledge graph specific to translational medicine, AIMed has crafted AI systems that are not only trustworthy but also deeply embedded in real-world medical scenarios. Additionally, the company has introduced an innovative AI Agent product designed to navigate the Freedom to Operate (FTO) challenges faced by innovative drugs as they embark on their global journey.

Jin Xia, the Founder and Chairman of AIMed, emphasized that this brand evolution reaffirms the company's steadfast commitment to the life sciences sector. He underscored the importance of ensuring that all AI product outputs are fully traceable, thereby enhancing transparency and accountability. Meanwhile, Chief Product Officer Tian Kaige highlighted the pivotal role of PharmaMark AI, the company's flagship Agent product. He explained how it can significantly mitigate infringement risks for pharmaceutical companies expanding internationally, while simultaneously boosting the success rate of translational medicine endeavors.

Looking ahead, the R&D team at AIMed has ambitious plans to unveil a slew of additional Agent applications by 2026, further solidifying its position as a trailblazer in the intelligent transformation of the translational medicine ecosystem. Notably, AIMed has already garnered authoritative recognition from the U.S. FDA, and its PharmaMark AI product suite has been embraced by regulatory bodies across multiple countries, cementing its global footprint.